Abstract
Despite being a mainstay of clinical cancer treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance. Nanotechnology-based drug-delivery systems are widely expected to bring new hope for cancer therapy. These systems exploit the ability of nanomaterials to accumulate and deliver anticancer drugs at the tumor site via the enhanced permeability and retention effect. Here, we established a novel drug-delivery nanosystem based on amphiphilic peptide dendrimers (AmPDs) composed of a hydrophobic alkyl chain and a hydrophilic polylysine dendron with different generations (AmPD KK2 and AmPD KK2K4). These AmPDs assembled into nanoassemblies for efficient encapsulation of the anti-cancer drug doxorubicin (DOX). The AmPDs/DOX nanoformulations improved the intracellular uptake and accumulation of DOX in drug-resistant breast cancer cells and increased permeation in 3D multicellular tumor spheroids in comparison with free DOX. Thus, they exerted effective anticancer activity while circumventing drug resistance in 2D and 3D breast cancer models. Interestingly, AmPD KK2 bearing a smaller peptide dendron encapsulated DOX to form more stable nanoparticles than AmPD KK2K4 bearing a larger peptide dendron, resulting in better cellular uptake, penetration, and anti-proliferative activity. This may be because AmPD KK2 maintains a better balance between hydrophobicity and hydrophilicity to achieve optimal self-assembly, thereby facilitating more stable drug encapsulation and efficient drug release. Together, our study provides a promising perspective on the design of the safe and efficient cancer drug-delivery nanosystems based on the self-assembling amphiphilic peptide dendrimer.
Highlights
Cancer is one of the leading causes of death around the world [1]
amphiphilic dendrimers (AmPDs) composed of hydrophobic C18 alkyl chain and different hydrophilic poly(Llysine) peptide dendrons (AmPD KK2 and AmPD KK2 K4 ) were synthesized according to the strategy described in Schemes S1–S4 (Supplementary Materials)
Despite being a mainstay in clinical treatment, chemotherapy is limited by its severe side effects and inherent or acquired drug resistance
Summary
Considerable achievements have been made in clinical cancer treatment, an effective cure remains a challenge [2]. The efficacy of chemotherapy—the mainstay of clinical cancer treatment—is limited by its severe side effects, which include high toxicity, poor tumor selectivity, and inherent or acquired drug resistance during or after chemotherapy [3,4,5]. One promising strategy is nanotechnology-based drug delivery systems (NDDSs) [6,7,8,9]. These NDDSs are able to facilitate the accumulation and delivery of anticancer drugs at tumor lesions via the enhanced permeability and retention (EPR)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.